Tweet
MARCH 23, 2021
By Daniel R. Lucey MD, MPH, FIDSA
... on March 10 the Department of Health and Human Services issued a statement that:
?The USG is evaluating recommendations for use of bamlanivimab in regions where the SARS-CoV2 mutation L452R found in B.1.429/B.1.427 lineages (a.k.a. 20C/CAL.20C) is circulating in high numbers given concerns that the clinical activity of bamlanivimab is impacted by this variant. ASPR will limit distribution to these regions of the country by stopping direct ordering for bamlanivimab while evaluations are ongoing.
Currently, this action will only affect the states of California, Arizona, and Nevada. The other two authorized products, bamlanivimab/etesevimab and casirivimab/imdevimab, do not appear to be affected and will continue to be available for direct ordering in these states.?
https://sciencespeaksblog.org/2021/0...-bamlanivimab/
By Daniel R. Lucey MD, MPH, FIDSA
... on March 10 the Department of Health and Human Services issued a statement that:
?The USG is evaluating recommendations for use of bamlanivimab in regions where the SARS-CoV2 mutation L452R found in B.1.429/B.1.427 lineages (a.k.a. 20C/CAL.20C) is circulating in high numbers given concerns that the clinical activity of bamlanivimab is impacted by this variant. ASPR will limit distribution to these regions of the country by stopping direct ordering for bamlanivimab while evaluations are ongoing.
Currently, this action will only affect the states of California, Arizona, and Nevada. The other two authorized products, bamlanivimab/etesevimab and casirivimab/imdevimab, do not appear to be affected and will continue to be available for direct ordering in these states.?
https://sciencespeaksblog.org/2021/0...-bamlanivimab/